✦ LIBER ✦

Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety

✍ Scribed by Beck, Michael

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label, switchover trial to asses

✍ Richards, Sarah; Laney, Dawn; Pervaiz, Muhammad A.; Shankar, Suma 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

A randomised, double-blind, placebo-cont

✍ Hughes, D.A.; Deegan, P.B.; Milligan, A.; Wright, N.; Butler, L.H.; Jacobs, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 283 KB

Effects of enzyme replacement therapy wi

✍ F Dehout; A Schwarting; M Beck; A Mehta; R Ricci; U Widmer; on behalf of the FOS 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

Long-term safety and efficacy data of ta

✍ Zimran, Ari; Mehta, Atul; Giraldo, Pilar; Rosenbaum, Hanna; Giona, Fiorina; Amat 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 59 KB

The Impact of New and Emerging Clinical

✍ ERIC N PRYSTOWSKY; JOHN CAMM; GREGORY Y.H. LIP; MAURITS ALLESSIE; JEAN-FRANÇOIS 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB

A comprehensive review of clinical trial

✍ Thomas J Schnitzer; Aimee Ferraro; Elke Hunsche; Sheldon X Kong 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 290 KB